Physician profile
Bruce E Wilson
NPI 1295826857
$352,273.38
in general payments reported to CMS, 2019-2025
43 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117K · 2020: $60K · 2021: $44K · 2022: $58K · 2023: $27K · 2024: $16K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Travel and Lodging: $13K · Food and Beverage: $7,174 · Consulting Fee: $5,813 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,872.45 |
| Travel and Lodging | $12,719.33 |
| Food and Beverage | $7,174.16 |
| Consulting Fee | $5,812.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $120,715.68 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $45,763.71 | 2020-2025 | Freestyle Libre 3, Freestyle Libre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40,839.41 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $35,013.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $33,431.91 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $19,722.86 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $16,299.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12,953.96 | 2022-2024 | |
| Corcept Therapeutics | $6,793.68 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $5,707.93 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $4,059.96 | 2019-2025 | Tepezza, Evenity, Prolia |
| Medtronic, INC. | $3,018.64 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Medtronic Minimed, INC. | $2,831.00 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $1,654.80 | 2019-2025 | Lokelma, Farxiga |
| Shire North American Group INC | $1,000.00 | 2019 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $335.93 | 2021-2025 | |
| Abbvie INC. | $278.75 | 2019-2025 | Creon |
| Recordati_rare_diseases_inc. | $177.33 | 2020-2025 | Isturisa, Signifor Lar |
| Tandem Diabetes Care, INC. | $164.24 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lexicon Pharmaceuticals, INC. | $147.17 | 2024 | Inpefa |
| Antares Pharma, INC. | $143.57 | 2019-2024 | Xyosted |
| Ascensia Diabetes Care US INC. | $103.27 | 2021-2024 | |
| Zealand Pharma US, INC. | $102.94 | 2021-2022 | |
| Insulet Corporation | $102.93 | 2019 | |
| Alexion Pharmaceuticals, INC. | $100.92 | 2023-2025 | Strensiq |
| Dexcom, INC. | $87.18 | 2019-2023 | Dexcom G6 Transmitter |
| Chiasma, INC. | $84.99 | 2021 | |
| Kyowa Kirin, INC. | $69.18 | 2023-2024 | Crysvita |
| Cequr Corporation | $66.25 | 2022-2024 | Cequr Simplicity |
| Neurocrine Biosciences, INC. | $65.98 | 2025 | |
| Ibsa Pharma INC. | $56.64 | 2022-2023 | Tirosint, Licart |
| Radius Health, INC. | $56.05 | 2019-2022 | |
| Madrigal Pharmaceuticals | $49.15 | 2025 | Rezdiffra |
| Grt US Holding, INC. | $45.05 | 2021-2022 | |
| Horizon Therapeutics Plc | $36.74 | 2023 | Tepezza |
| Amarin Pharma, INC. | $30.15 | 2020-2021 | |
| Ascendis Pharma Endocrinology INC | $27.81 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $26.08 | 2019 | |
| Lifescan, INC. | $25.36 | 2020 | |
| Sequel Med Tech, LLC | $24.94 | 2025 | Twiist |
| Soleno Therapeutics, INC. | $23.49 | 2025 | Vykat Xr |
| Ultragenyx Pharmaceutical INC. | $17.31 | 2022 | |
| Eusa Pharma (US) LLC | $17.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.